Molina Healthcare Inc

NYSE:MOH

Earnings Call Transcript 2022-Q4

[Operator]

Good morning, and welcome to Molina Healthcare’s Fourth Quarter 2022 Earnings Call. All participants will be in listen-only mode. [Operator Instructions] After today’s presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded.

I would now like to turn the conference over to Joe Krocheski, Senior Vice President, Molina Healthcare. Please go ahead.

[Joe Krocheski, SVP, IR]

Good morning, and welcome to Molina Healthcare's fourth quarter 2022 earnings call. Joining me today are Molina's President and CEO, Joe Zubretsky; and our CFO, Mark Keim. A press release announcing our fourth quarter earnings was distributed after the market closed yesterday and is available on our Investor Relations website.

Shortly after the conclusion of this call, a replay will be available for 30 days. The numbers to access the replay are in the earnings release. For those of you who listen to the rebroadcast of this presentation, we remind you that the remarks made are as of today, Thursday, February 9, 2023. It has not been updated subsequent to the initial earnings call.

On this call, we will refer to certain non-GAAP measures. A reconciliation of these measures with the most directly comparable GAAP measures for 2022 and 2023 can be found in our fourth quarter 2022 press release.

During our call, we will be making certain forward-looking statements, including, but not limited to, statements regarding our 2023 guidance, our projected 2024 outlook and revenue, our recent RFP awards, recent and future RFP submissions, including those in Indiana, New Mexico and Florida, our acquisitions and M&A activity, Medicaid lease terminations, our long term growth strategy and our embedded earnings power and margins.

Listeners are cautioned that all of our forward-looking statements are subject to certain risks and uncertainties that could cause our actual results to differ materially from our current expectations. We advise listeners to review the risk factors discussed in our Form 10-K annual report filed with the SEC, as well as the risk factors listed in our Form 10-Q and Form 8-K filings with the SEC. After the completion of our prepared remarks, we will open the call to take your questions.

I will now turn the call over to our Chief Executive Officer, Joe Zubretsky. Joe?

[Joe Zubretsky, President & CEO]

Thank you, Joe, and good morning. Today, we will provide updates on several topics. Our financial results for the fourth quarter and full year 2022, our initial 2023 revenue and earnings guidance, our growth initiatives and our strategy for sustaining profitable growth, and our outlook on premium revenue for 2024, given our new business successes in 2022.

Let me start with the fourth quarter highlights. Last night, we reported fourth quarter adjusted earnings per diluted share of $4.10, representing 42% growth year-over-year. Our fourth quarter 88.3% consolidated medical care ratio, 7.5% adjusted G&A ratio, and 3.9% adjusted pretax margin demonstrate continued strong operating performance. The fourth quarter completes another strong year of operating and financial performance. For the full year, we grew premium revenue by 15% to approximately $31 billion and grew adjusted earnings per share by 32% to $17.92.

Our full year adjusted pretax margin of 4.4% was squarely in line with our long-term targets. Medicaid, our flagship business representing approximately 80% of enterprise revenue continues to produce very strong and predictable operating results and cash flows. For the year, we grew membership by approximately 10% and premium revenue by 21%, driven by the inception of our Nevada Medicaid contract, recently closed acquisitions and organic growth.

The rate environment is stable and we are executing on the fundamentals of medical cost management. The full year reported MCR of 88% is at the low end of our long term target range and consistent with pre-pandemic levels, reflecting the underlying strength of our diversified portfolio and our focused execution.

Our high acuity Medicare niche serving low income members representing 12% of enterprise revenue, continues to grow organically and demonstrate strong operating performance. For the year, we grew membership by 10% and premium revenue by 13%. Membership growth was driven primarily by our low income MAPD product, which more than doubled in 2022. The full year reported MCR of 88.5% was modestly above our long term target range, but includes approximately 300 basis points of pressure from COVID-related care.

In Marketplace, the smallest of our three lines of business, we repositioned the business both in terms of its size in the portfolio and metallic mix. On a pure period basis, the business performed at roughly breakeven. While the financial performance did not meet our initial expectations for the year, we believe we have positioned our marketplace business to achieve target margins in 2023.

Turning now to the execution of our growth strategy for the year. The successes in 2022 were many. On the M&A front, we closed on the acquisition of Cigna's Texas Medicaid business at the beginning of the year. And the AgeWell acquisition, at the beginning of the fourth quarter. In July, we announced the My Choice Wisconsin acquisition further adding to our market leading LTSS franchise.

Our performance on Medicaid RFPs in the year was exceptional. We renewed our contract in Mississippi, doubled the size of our California contract for 2024 and won two new contracts: first in Iowa and then Nebraska for a 100% win rate on RFP responses submitted. In total, we project that these RFP wins for the year will add $4.4 billion in run rate premium revenue. In summary, our full year 2022 enterprise results continue to demonstrate our ability to produce excellent margins, while expanding our franchise by growing premium revenues.

Turning now to our 2023 guidance. You can easily see the results of the repeatable earnings pattern we have created. We built new store contract backlog and harvest the earnings as the contracts and acquisitions mature. Meanwhile, we continue to focus on the operating fundamentals and drive operational improvements, which allows us to grow the core business at attractive margins.

With regard to our 2023 guidance, we project 2023 premium revenue of $32 billion, representing a 19% compound annual growth rate since our pivot to growth in 2019. The 2022 earnings per share of $17.92 serves as a solid high margin earnings jump-off point. We expect that $1 per share of prior embedded earnings will emerge into 2023 earnings. We expect to produce $1.50 per share of core growth and operational improvements.

We expect all of these elements will combine to produce 2023 core earnings per share of at least $20.40, offset by $0.65 per share of one-time contract implementation costs, which results in our 2023 adjusted earnings per share guidance of at least $19.75. The operating improvements supporting the margins in our guidance are durable. The various elements which could impact earnings, COVID, flu, RSV, any margin impacts from redeterminations have been considered informing our guidance.

The metrics implied by guidance are squarely in line with our long-term target ranges. As our guidance produces a 4.7% pretax margin, with a growth rate of 14% in core earnings and 10% on a reported adjusted basis. This is an attractive growth profile in a model that is repeatable. In addition to the growth within our guidance, we continue to build an earnings base for the future in the form of our embedded earnings profile, which provides a forward view of our earnings potential beyond 2023.

The new store component of our embedded earnings defined as earnings from achieving target margins on acquisitions and new Medicaid contract wins is now at least $4 per share. The ongoing net effect of COVID, which at this point is the continuing earnings impact from the three remaining risk corridors, adds $2 per share of additional upside to this figure. This latent earnings growth estimate does not take into consideration any future organic growth or future strategic initiatives.

Turning now to our growth strategy. We have taken major strides toward our $42 billion 2025 premium goal. At this early stage, we already have a clear line of sight to $35.5 billion in 2024. The key to our strategy is balanced, a stellar record of new contract wins, Kentucky, Nevada and now filling in the middle part of the country. The doubling of the size of our California business, including significant expansion in Los Angeles County, preserving and securing all of our incumbent state contracts and no large reprocurements in the near-term, continuing to build the M&A pipeline as this aspect of our strategy has already produced seven transactions for $10 billion. in revenue. Not to mention, organic growth, one member at a time by focusing on greater member attraction and retention and overcoming the regulatory headwinds of redeterminations and pharmacy carve outs.

With that as the backdrop, I will now provide an update on some specific in flight opportunities related to our long term growth strategy. At the end of January, the Texas Health and Human Services Commission posted a notice on its website indicating that it was issuing a notice of intent to award our Texas Health Plan, a contract for all of our existing eight service areas in the state. We expect to be able to provide more of an update once these contracts have been finalized and signed.

Our RFP response for the Indiana LTSS program has been submitted, it is pending evaluation and subsequent award announcement. In New Mexico, the state announced it has terminated the RFP that was in process and according to their press release, intends to issue an expedited reprocurement as soon as possible. We have many other new state business development initiatives well underway, including the potential for expanding to our former nearly statewide footprint in Florida.

Our growing Medicaid footprint still only represents half of the 41 states with managed Medicaid. With multiple new state RFP opportunities over the coming years, and our demonstrated capabilities, referenceability and track record, we remain confident in our ability to win additional new state contracts. Our acquisition pipeline remains replete with actionable opportunities. While the timing of transactions remains difficult to predict, the strength of our pipeline and our track record of success gives us confidence in our ability to drive further growth from this important element of our growth strategy.

In summary, we are very pleased with our business performance and the progress made in 2022 on our growth strategy, which has created a solid and growing financial profile. At least $20.40 of core earnings per share and $19.75 per share of adjusted earnings in 2023. Current new store embedded earnings power of at least $4 per share with an additional $2 of upside, if and when the few remaining COVID era corridors are eliminated. And $35.5 billion of identified premium revenue in 2024. All of this is before any impact from the continued execution of our growth initiatives.

Of course, we could not accomplish all of this without our excellent management team and dedicated associates now approaching 15,000 strong, who in concert with our hallmark, proprietary operating model and management process have produced these results. To the entire team, I once again extend my deepest thanks in heartfelt appreciation.

With that, I will turn the call over to Mark for some additional insight on the financials. Mark?

[Mark Keim, CFO]

Thanks, Joe, and good morning, everyone. Today, I will discuss some additional details on our fourth quarter and full year performance, our strong balance sheet and our 2023 guidance. Beginning with our fourth quarter and full year results, our consolidated MCR for the fourth quarter was 88.3%, reflecting continued strong medical cost management.

For the quarter, flu, RSV and COVID-related medical costs in total were largely in line with our expectations, but the impact varied by line of business, with Medicare being disproportionately impacted. Our full year consolidated MCR was 88%. This result was consistent with our expectations and was driven by the continued strong performance of our flagship Medicaid business.

In Medicaid, our fourth quarter reported MCR was 87.3%. This strong performance was driven by effective medical cost management, and favorable retroactive premiums. The net effect of COVID in the quarter was a modest 30 basis points within our reported MCR. Our full year Medicaid MCR of 88% was at the low end of our long term target range and consistent with pre-pandemic levels.

In Medicare, our fourth quarter reported MCR of 91.8% was driven by higher COVID, flu and the mix effect of our significant growth in MAPD. During the quarter, the net effect of COVID was 300 basis points within our reported MCR. Our full year Medicare MCR was 88.5% modestly above our long term target range and was similarly burdened by 300 basis points of net effect of COVID. In marketplace, our reported fourth quarter MCR was 93.8%. The MCR was impacted by normal seasonality and increased utilization in a handful of markets. The net effect of COVID was approximately 50 basis points within our reported MCR.

In the quarter, we also settled some provider balances dating to prior years, which disproportionately impacted our Marketplace MCR by approximately 300 basis points. Our full year Marketplace MCR of 87.2% exceeded our long-term target range and includes approximately 120 basis points of net effective COVID, as well as approximately 130 basis points from the impact of a 2021 risk adjustment true-up recorded in the second quarter.

Additional drivers of our strong fourth quarter and full year results include a 7.5% fourth quarter adjusted G&A ratio, which was in line with expected seasonal expenditures related to open enrollment and spending on community and charitable activities. Our full year adjusted G&A ratio improved year-over-year to 7.1% as we remain focused on delivering fixed cost leverage as we grow, even while making the appropriate investments to sustain our growth. Fourth quarter and full year results also feature higher net investment income as expected from recent increases in interest rates.

Turning now to our balance sheet. Our reserve approach remains consistent with prior quarters, and we continue to be confident in our reserve position. Days in claims payable at the end of the quarter was 47%, about three days lower sequentially. The decline was driven by the increased mix of LTSS claims, which settled more quickly, resulting from the closing of the AgeWell acquisition as well as an additional payment cycle in the quarter.

Our capital foundation remains strong. Debt at the end of the quarter was 1.8 times trailing 12-month EBITDA, and our debt-to-total cap ratio was 44.9. On a net debt basis, net of parent company cash, these ratios fall to 1.5 times and 40.7%, respectively. Our leverage remains low. All bond maturities are long dated on average eight years and our weighted average cost of debt fixed at just 4%.

In the quarter, we harvested $268 million of subsidiary dividends and repurchased approximately 590,000 of our shares. Parent company cash at the end of the quarter was $375 million. With substantial incremental debt capacity, cash on hand and strong cash flow to the parent, we have ample dry powder to drive our organic and inorganic growth strategies.

2022 full year operating cash flow was lower compared to the prior year, primarily due to the cash settlement in 2022 of large prior year marketplace risk adjustment and Medicaid risk corridor payments. Normalizing for the timing of these payments, 2022 operating cash flow was $1.6 billion.

Turning now to our 2023 guidance, beginning with membership. In Medicaid, we expect organic growth, the midyear inception of the Iowa contract and membership from our My Choice Wisconsin acquisition to be largely offset by the second quarter resumption of redeterminations. We expect this to result in 2023 year-end membership of approximately 4.7 million members.

In Medicare, based on our performance in the annual enrollment period, we expect to begin the year with 160,000 members and continue to grow during the year, ending 2023 with total membership of approximately 175,000 members. Our Medicare membership growth for 2023 is expected to be evenly split between our D-SNP and MAPD products.

In Marketplace, based on open enrollment, we expect to begin 2023 with approximately 290,000 members, reflecting our pricing strategy to achieve target margins in this business for 2023. Accounting for a limited SEP and normal levels of attrition through the year. We expect to end 2023 with approximately 230,000 members. We continue to treat any marketplace membership from Medicaid redeterminations as upside to these projections.

Moving on to premium revenue. Our 2023 premium revenue guidance is $32 billion, representing 4% growth from 2022 Our revenue guidance is comprised of several items, $1.2 billion for the full year impact of AgeWell and expected revenue from the My Choice Wisconsin acquisition when closed. $1 billion of organic growth in Medicaid and Medicare and $900 million for the midyear inception of our new Iowa contract.

Several offsetting items include: $600 million for the known pharmacy carve-outs, $500 million for the impact of the resumption of redeterminations beginning in April, $600 million for the lower Marketplace membership, and $300 million in 2022 pass-through revenue that we don't expect to recur in 2023.

Turning to earnings guidance. We expect full year adjusted earnings to be at least $19.75 per share. Our EPS guidance reflects the realization of approximately $1 per share of 2022 embedded earnings, consisting of the contribution from acquisitions and a portion of the net effect of COVID partially offset by the impact of redeterminations.

To this, we add $1.50 for the underlying organic growth plus several operating levers, including our real estate reduction strategy, the full year effect of our PBM contract and net investment income, partially offset by the negative impact of known pharmacy carve-outs. These drivers combined to deliver core earnings per share of at least $20.40. Recognizing the one-time non-recurring implementation costs in 2023 for our new contract wins that we now project to be $0.65 per share, yields our 2023 earnings per share guidance of at least $19.75.

Moving on to select P&L guidance metrics. We expect our consolidated medical care ratio to be approximately 88%, consistent with our 2022 results. We expect our adjusted G&A ratio to fall slightly to 7%, even while absorbing the impact of the one-time non-recurring implementation costs for our new contract wins. This reflects disciplined cost management and fixed cost leverage from our revenue growth.

Excluding the new contract implementation costs, our adjusted G&A ratio would have improved year-over-year to 6.8%. The effective tax rate is expected to be 25.3%, adjusted after-tax margin is expected to be 3.5%, well within our long-term target range. Weighted average share count is expected to be 58.1 million shares. And we expect our quarterly adjusted earnings per share profile to be fairly flat over the year, with the first two quarters of the year at roughly $5 each.

As Joe mentioned, our 2023 new store embedded earnings power is at least $4 per share and is comprised of at least $3.50 from our three recent new contract wins, and $0.50 per share for AgeWell and My Choice Wisconsin acquisitions, achieving full accretion. We continue to carry approximately $2 for COVID era risk corridors providing additional potential upside to be at least $4 of new store growth embedded earnings.

I'll now turn the call over to Joe for some concluding remarks. Joe?

[Joe Zubretsky, President & CEO]

Thanks, Mark. In looking back over the past five years, we pause briefly to reflect on our company's accomplishments. We won $5 billion in new Medicaid awards over the period and defended all of our existing contracts. We acquired $10 billion in profitable revenue. In short, we doubled the revenue base. We have produced industry-leading margins in our core products, averaging 4% to 5% on a pretax basis.

The top line growth and margin expansion allowed us to grow earnings per share from a loss in 2017 to nearly $20 per share in 2023 guidance. We've ascended to Fortune 125 status and were promoted into the S&P 500. We have a pure-play government managed care franchise to grow and build on. We only take this retrospective journey to express our excitement, enthusiasm and energy for the next five years. There are so many more opportunities to continue to grow and expand our franchise.

As we say here at the company, reaching milestones is not a cost for celebration, but a cause for consternation as reaching one merely marks the point in time to set new aspirational goals. We plan to share our view over the next five years with you at an Investor Day later this year.

This concludes our prepared remarks. Operator, we are now ready to take questions.

[Operator]

We will now begin the question-and-answer session. [Operator Instructions] The first question comes from Josh Raskin with Nephron Research. Please go ahead.

[Josh Raskin, Nephron Research]

Hi. Thanks. Good morning. So the guidance for the 2023 MLR is overall flat. I assume it would be fair to expect the Marketplace MLR to be down meaningfully. But even just based on size, probably not a meaning contributor. Would it be fair to assume that the Medicaid MLR embedded in there is actually up? And maybe you could help quantify some of those absolute changes by segment and maybe specifically how reterminations are impacting your view of the Medicaid MLR?

[Joe Zubretsky, President & CEO]

Sure, Josh. That is correct. We are going to produce a consolidated medical care ratio of 88% in each of 2022 and our guidance through 2023. We get there in a slightly different way year-over-year. Obviously, with our repositioning of the Marketplace business, we're projecting that with pricing actions, with the small silver and stable strategy, we will bring that MCR down within the long-term range at the high end of the long-term range of 78% to 80%.

Medicare slightly underperformed our long-term target for the year because of 300 basis points of pressure. We now project that Medicare will come into its long-term target range, perhaps in the middle of that range. And yes, because we have been outperforming our long-term guidance range in Medicaid, 80% of our revenue, we are forecasting a reversion to the mean, considering all the impacts of flu, RSV, COVID, any potential nuanced reaction to retermination process puts us in the middle of the range at 88.5%, our long-term range being 88% to 89%. So that's the line of business tail of the tape for MCR projection into 2023.

[Mark Keim, CFO]

That's right, Joe. Josh, it's Mark. Total guidance at 88% MLR. As Joe mentioned, each of the segments I've got pretty much right in the middle of long-term guidance. So think of Marketplace, 79% to 80%; Medicare Advantage 87.5% and Medicaid, call it, 88 5%. For weightings, pretty similar to what we had this year, probably about 5% marketplace, which is a little bit smaller as the portfolio about 13% Medicare Advantage, about 82% in Medicaid. So you round all that out.

The only other thing I'd say is, we finished full year Medicaid in 2022 at an 88%. We're obviously in our guidance saying an 88.5% roughly for Medicaid. So that's an additional 50 basis points for new stores, who knows redetermination or just general conservatism, but that's how I'm thinking about the MLRs there.

[Josh Raskin, Nephron Research]

Okay. So no specific explicit redetermination, but sort of capturing it in that 50 basis points of general conservatism?

[Mark Keim, CFO]

That's the way to think about it, Josh.

[Josh Raskin, Nephron Research]

Perfect. Thanks.

[Operator]

The next question comes from A.J. Rice with Credit Suisse. Please go ahead.

[A.J. Rice, Credit Suisse]

Thanks. Hi, everybody. Maybe I'll just -- I know it's a smaller portion, but on the public exchanges or marketplace, your decline in enrollment. I know you've been talking about for a while that for '23, you would price for margin. Are you surprised -- was that decline in enrollment consistent with what you thought. It seems like, as we hear from your peers and everyone, there's quite a divergence in and what people are seeing. Any comment you can make on what you saw in benefits as this market become very sensitive to slight changes because some people are showing huge growth, others are not. And I'm just trying to put that in perspective.

And then you're saying you do not have any assumption that you'll pick up lives on the public exchanges as redeterminations play out. Can you give us a sense of what that might look like possibly if you're not baking in the guidance? And do you have any view? I know there's been a lot of discussion about how those redetermined lives when they come on the public exchanges might affect the risk pool, I'm assuming that net-net, because you don't have anything in there, you think it would be a positive for you, even if maybe they're a little sicker than your average person on the exchanges today. But anyway, just fleshing out some of the public exchange commentary.

[Joe Zubretsky, President & CEO]

Sure, A.J. The membership results starting the year with 290,000 members, finishing the year with 230,000 members. We'll aggregate to about $1.6 billion in premium for the year. And that was fully in line with our expectations with respect to our pricing strategy. Look, we're allocators of capital and this business has shown that due to the instability of the risk pool by the introduction of the special enrollment period and other factors that it does have some inherent volatility.

There also has been some irrational pricing over the past couple of years. So pushing the pause button and going silver stable, in small was exactly the right approach and the business for 2023 has landed in a good place for us to achieve our mid-single digit margin target, if we conclude that the risk pool has stabilized due to the lack of government movement of the risk pool rules, pricing is rational, we likely would conclude to allocate more capital to this line of business and grow it again.

Mark, anything to add?

[Mark Keim, CFO]

Yeah, A.J., good morning. As Joe mentioned, starting off with 290,000 members going down, I think, to 230,000 by the end of the year, really exactly what we expected. We put 9% rate into the market this year. If you look at the mix of what we got and the pricing we put into the market, so with 9% not surprised with that result at all. Now you asked about the MLRs. To the extent we pick up folks from redetermination, I'm expecting the MLRs coming over to be quite consistent with our underwriting range. Those folks will not be new to health insurance. They will not be coming in with pent-up demand. So I'm expecting a pretty stable pool as they come over.

[A.J. Rice, Credit Suisse]

Okay. That’s great. Thanks a lot.

[Operator]

The next question comes from Justin Lake with Wolfe Research. Please go ahead.

[Justin Lake, Wolfe Research]

Thanks. Good morning. A couple of questions on the numbers side. First, on Medicaid membership, can you give us the membership? I know it's going to be flat. You talked about some new growth of acquisitions offsetting redeterminations. Can you give us those numbers in terms of what you're expecting there for each of those buckets? And then, how should we think about redeterminations from '23 into 2024 in your mind?

And then on the reserves, I've heard you talk about DCP and I saw in the release that you mentioned a bunch of payments in the quarter. I did go back and take a look at fourth quarter paid versus fourth quarter kind of reserved or medical costs, last year to this year, it didn't look like there was a significant change in paid claims as a percentage of total in the fourth quarter of this year versus last year. So hoping you could just flesh that out a little bit in terms of what you were seeing there? Thanks.

[Mark Keim, CFO]

Great. So a bunch there, Justin. Let me start with Medicaid. We ended 2022 with about 4.7 million members. As Joe mentioned earlier, I expect to conclude 2023 with about the same. We'll go in there. The moving pieces is redetermination probably around 300,000 or more coming off, but replaced by a number of good guys. For example, the Iowa acquisition about 200,000 members, the My Choice acquisition about 40,000 members; California fee-for-service coming in a bunch of offsets there. So pretty much flat over the year from a membership perspective.

On the DCP, you're talking about and the payments related to medical expenses. In general, when I look at DCP and I look at our reserving, our purchase is the same. It's the same actuarial on leadership, same approach to development and our triangles, the same external audit review. So I feel very confident about our process. What has changed is, in the fourth quarter, we added AgeWell, which brought in the LTSS membership, that membership adjudicates a whole lot faster and pays a whole lot faster. We also had the extra payment cycle. So when I look at the fourth quarter, we actually paid more than what I recorded in medical expense. So that's driving a bunch of that DCP decline from 50 to 47. Hope that helps.

[Justin Lake, Wolfe Research]

Right. Thanks for the color.

[Operator]

The next question comes from Calvin Sternick with JPMorgan. Please go ahead.

[Calvin Sternick, JPMorgan]

Hey. Good morning. Just a quick follow-up. It sounded like you said if the marketplace was stable, you could look to grow it again next year. And that just sounds a little different than some of your previous comments where you kind of let the membership float up and down year-to-year. I just want to understand that in the context of your overall strategy. Is the growth outlook for Marketplace just based on your evaluation in the market this year, and that's something that you look to reevaluate next year or are you saying that you kind of want to grow Marketplace going forward.

[Joe Zubretsky, President & CEO]

Now in that line of business, we are going to look at the stability of the risk pool, chasing and moving target with respect to the government rules around who's eligible, how many people are eligible when they become eligible has thrown in the past couple of years, that risk pool into what we consider to be a period of instability. If that should stabilize and now we're convinced that the pricing that's put into the market by us and the competitors is rational.

I've always said, we could put this business back into the growth category, allocate more capital to it and grow it, but grow it in a very responsible and measured way. So I'm not sure, we're seeing anything new, but right now, keep it small silver and stable until we conclude that we should allocate more capital to it and grow it in a very measured and responsible way. And that's been our strategy all along.

[Calvin Sternick, JPMorgan]

Got it. And I know you're not forecasting growth from Marketplace from redeterminations. But just curious if you have a sense for what the recapture rate was pre-COVID. So when someone got redetermined in Medicaid, how long did they typically go uninsured before they got coverage elsewhere? And I guess how often are you able to recapture some of those members in a Molina Marketplace product?

[Joe Zubretsky, President & CEO]

The way I would answer that is one of the reasons we haven't forecasted to capture is because the data around how it's worked in the past is pretty imprecise. I mean we could create all the models with various scenarios. We decided not to forecast it. We have operational protocols in place with member outreach in the states that allow that through text, phone and mail to help members reestablish eligibility and if determined that they are ineligible for Medicaid but eligible for a highly subsidized Marketplace product, we will then warm transfer them over to our distribution channels for Marketplace and capture them in that manner. But because this is uncharted waters, it's just -- it's never been done before, we chose not to create a model and forecast it, but consider it as upside to our membership growth.

[Calvin Sternick, JPMorgan]

All right. Great. Thanks.

[Operator]

The next question comes from Scott Fidel with Stephens. Please go ahead.

[Scott Fidel, Stephens]

Hi. Thanks. Good morning. I guess, I'll use my question just to try to fill out a couple of the other modeling elements for 2023. Just interested if you could give us your thoughts on operating cash flow, and then also investment income and interest expense for 2023?

[Mark Keim, CFO]

Sure. Scott, it's Mark. So when I think about operating cash flow, I focus on cash flow at the parent because that's what restocks my firepower. I expect to take pretty meaningful dividends. I've got a few acquisitions to pay for this year and I've got some growth organically that I need to fund. So all told, at the parent, I expect to have more than $0.5 billion by the end of the year.

Interest expense, you can model going forward, you know my bonds, you know my rates. On interest income, that's a wildcard, right? We're all guessing on that. finishing 2022 with about $7.5 billion of cash and investments. I expect across 2023 to end the year with about $7 billion of cash and investments, including everything at the subs.

Now the wildcard here is, what kind of an interest rate to put on that, right? We've had one Fed raise already this year. If you look at the Fed Funds future rates. We've got maybe one more raise coming and maybe one or two declines back half of the year. So how do I think about that across the year? Not quite sure. I think you could model any place between mid and high 2s on a yield basis and come out with a pretty credible interest forecast there.

[Scott Fidel, Stephens]

Okay. Thanks. And just one quick follow-up question. Just on the M&A side, how you're thinking about the pipeline and sort of the pacing of engagement in 2023. Obviously, you've got some significant installations of new business in flight. So interested in how you're thinking about layering in M&A as well. Thanks.

[Joe Zubretsky, President & CEO]

Yeah, Scott. Even with the significant backlog of both integrations on in-flight acquisitions and new contract implementations and our new wins, we have continued to aggressively pursue the M&A pipeline. And nothing has really changed with respect to the appetite of single state operators not for profit plans to listen to the Molina story and want to be part of this larger enterprise, where they continue -- they can continue to fulfill their local mission and have access to the broad and deep capabilities and financial resources that we bring. So it's a great story and nothing has really changed there. I would say, given the size of the pipeline and the level of activity and the maturity of some of the opportunities, we feel very confident in some announcements here in 2023.

[Scott Fidel, Stephens]

Okay. Thank you.

[Operator]

The next question comes from Michael Hall with Morgan Stanley. Please go ahead.

[Michael Hall, Morgan Stanley]

Hi. Thank you. Just wanted to touch on the marketplace, again and just ask about like what happened in '22. So at the beginning of the year, you're expecting 79% MLR, but Q2 I think there was a large miss really full year expectation to 84%. And then this past quarter, even excluding the 300 bps of scheduling past provided balances still ended up higher than expected. Now you're at 87% to end the year.

So I thought pricing was more disciplined than you went through this major recalibration of your metal peers to cover. So I would have expected more MLR stability than what we saw. Could you walk us through about like what happened with Marketplace and why the large divergent from initial expectations?

[Joe Zubretsky, President & CEO]

Sure. And as we said in our prepared remarks, even with the exclusion of the one-time items, the COVID-related items the risk adjustment true-up in the middle of the year. And in the fourth quarter, the significant settlement of some prior year provider balances, we did not meet our expectations in marketplace. The continuing MLR drag from that significant SEP membership that renewed into the current year, continued to drag on the MLR.

We now believe that the special enrollment period might produce this year 3,000 to 4,000 a month, where it was producing 20,000 to 25,000 a month and the height of the SEP gives the risk full more stability, and we're priced for it. So we did not meet our expectations even while ignoring the one-time items. But this year, we feel that with the high-single digit price increase, low-single digit trend, good visibility on our renewal membership to make sure we get appropriate risk scores that we're in good shape to hit mid-single digit margins in 2023.

[Operator]

The next question comes from Stephen Baxter with Wells Fargo. Please go ahead.

[Stephen Baxter, Wells Fargo]

Yeah. Hi. Thanks. I wanted to follow up on the Medicaid MLR question. I appreciate the color on your expectations. How should we think about Medicaid MLR? I know you probably want to guide it too close quarterly, but do you expect to generally operate around that 88.5 level kind of consistently throughout the year or is there any slope to that line that we should maybe be thinking about?

And then just to kind of put a bow on the question on the DCP for the AgeWell business, could you just give us a sense of what the DCPs would look like on a stand-alone basis, we can try to put that into context? Thanks.

[Joe Zubretsky, President & CEO]

So I'll turn it to Mark. But yes, given the mix of the business has changed and many of the dynamics of the businesses have changed, the seasonal patterns of how MCRs emerge, has changed slightly over time. So I'll turn it to Mark to give you a view of how Medicaid might perform over the quarters.

[Mark Keim, CFO]

Yeah. I'm expecting pretty flat. And if you look historically, we've run pretty consistently on Medicaid, certainly more so than Medicare in the marketplace. So I think you can model that one pretty straight line. On the AgeWell, we'll follow up with you offline. I don't have a discrete number on that. I know what it does to my weighted average, but we can follow-up with that. Thank you.

[Operator]

The next question comes from Nathan Rich with Goldman Sachs. Please go ahead.

[Nathan Rich, Goldman Sachs]

Great. Thanks for the questions. You mentioned the $2 per share of earnings power from the three remaining COVID risk corridors. What's the time line to potentially realize these earnings? And then just more generally on state rates, how do you think the process plays out for states potentially revisiting rates as redeterminations occur and potential changes to the underlying risk pools take place. How do you think the states are going to approach that? Thank you.

[Joe Zubretsky, President & CEO]

Sure, Nathan. We actually consciously separated the two major components of our embedded earnings because one of them is, in our view, entirely controllable, harvesting the $4 of earning our target margins on latent contracts and M&A is something we have a proven track record of doing. We separated that from the $2 of lingering COVID era corridors because eliminating them is outside our control. They were put in place during COVID. They're articulated as being related to COVID. There are three remaining two that matter. Washington, State of Washington and Mississippi, and we believe over time that they will either be compressed or eliminated, but we don't control that.

With respect to rates, I would say that states, our customers and their actuaries are vary at least aware of the potential for an acuity shift somewhere due to the redetermination process. And the fact that they're aware of it. And we would -- and if or not, we will certainly make them aware if we experience it, leads us to believe that if there is a significant shift in acuity somewhere in the book of business that the actuarial soundest principle will prevail, and we'll be able to have a productive conversation about that.

[Mark Keim, CFO]

Nathan, just to build on that, a number of our states were in 19 on Medicaid now. A number of our states have told us, if and when there's any impact from that redetermination, they are quite willing to reopen that to revisit it. So we feel good between that commitment and our advocacy efforts that the rates will move as they need to.

[Nathan Rich, Goldman Sachs]

Thank you.

[Operator]

The next question comes from Gary Taylor with Cowen. Please go ahead.

[Gary Taylor, Cowen]

Hey. Good morning, guys. Most of my questions are answered, just two quick ones. One on the exchange membership loss driven by repricing. Is there any particular state you'd point out in your footprint or is that pretty evenly distributed that rate increase in the enrollment decline? And then just secondly, because 99% of all the incoming investor angst about Molina is around redetermination risk and potential impact on margins, et cetera.

Just wondered if you could share with us any additional work you've done on low utilizers, zero utilizers, people, populations most likely to be redetermined, et cetera? I know you've shared some of that before and just anything else you might add to provide some comfort around your Medicaid, MLR guide would be helpful, I think. Thanks.

[Joe Zubretsky, President & CEO]

Gary, I'll answer your second question first and then kick it to Mark for more detail. But the analysis that we've shared with you and investors is the same one, because we're looking at all the data. And there's so many theoretical arguments of why an acuity shift could happen. We focus on the numbers and the data. We look at members greater than one year duration, less than one year duration. We look at the MLR for members with less than one year duration, greater than one year duration. We look at members with zero to 25% MLRs.

We look at the lapse rate of membership, which hasn't gone to zero. There still is a disenrollment rate that occurs in the Medicaid book. So we look at all that data, and it leads us to believe that while maybe somewhere there could be a slight acuity shift probably in the expansion book, not in the tenant book or the ABD book, but manageable and will be easy to deal with, particularly because the states are aware of it and we believe we'll have a productive rate discussion if and when there is a shift in acuity that makes the rates actually unsound. Mark?

[Mark Keim, CFO]

Yes. So we update this analysis every quarter and the conclusion is really not changing. Joe mentioned a couple of the data points, the folks with us more than one year versus less the folks in the zero to 25% MCR bucket. Expansion, we're seeing a little bit of an increase, but across the board is not much. Remember, expansion is just 30% of our total revenue. The other data point that some folks have been talking about is coordination of benefits or duplication of benefits, do we see any increase in that population. Once again, not really, a little bit of an expansion.

So across the board, is there something here? Maybe, but it's really minimal. So again, not expecting much of an impact here to the extent it plays out. Now I refer back to the previous question, where I think the states are quite amenable to revisiting it. On your first question, are we fairly even distributed on our Marketplace? Yeah. I don't see any real estate density in any outliers of one state being disproportionately dense. We've got pretty good distribution across our 14 states here.

[Gary Taylor, Cowen]

Thank you.

[Operator]

The next question comes from Steven Valiquette with Barclays. Please go ahead.

[Steven Valiquette, Barclays]

Great. Thanks. Good morning. So just a follow-up question on the exchange business. Here you mentioned the shift from bronze to silver has been the right move the better margin profile demonstrates that. So I know you talked about this more a year ago, but just remind us again why bronze has proven to be more tricky from your point of view. Has that gotten better or worse currently versus a year ago? What would have to change within that just to give you comfort to reexplore bronze on a greater level? Thanks.

[Joe Zubretsky, President & CEO]

Steven, it's really an anomaly of the product design, not anything that we design, but the way the product is priced from an industry perspective, where one thing I can point to that is absolute fact is for the same member in bronze and silver with the same acuity level, the same services and therefore, the same HCCs, the risk score produces less revenue in bronze than it does in silver. And there are other aspects of it that make it just slightly less attractive. Mark?

[Mark Keim, CFO]

Yeah. I'd say a couple of things just building on Joe's thoughts. It's a lower actuarial value product. Sometimes that attracts folks that don't think they're going to use a product but do, the way the rules are set up, the balance on risk adjustment is a whole lot better on gold and silver than it is on bronze. And finally, just at a lower revenue load, it becomes slightly less attractive from a G&A perspective and some of our other operating ratios. You take those things all together, it's more volatile, and we just don't see the margins there.

[Steven Valiquette, Barclays]

Okay. Thanks.

[Operator]

The next question comes from George Hill with Deutsche Bank. Please go ahead. Mr. Hill, I'm not sure, some trouble hearing you. All right, your connection may have gone down. We'll go to the next questioner, who's Kevin Fischbeck with Bank of America. Please go ahead.

[Kevin Fischbeck, Bank of America]

Great. Thanks. One quick clarification question before I jump into the real question. The $6 of embedded earnings, it wasn't 100% clear to me. Is that in addition to the $0.65 coming back or is that $0.55 in the 3.50?

[Mark Keim, CFO]

So the total of $6 is $4 of new store EPS; $2 of net effective COVID; and there are two other items in there that cancel each other out. There's the implementation costs, which are a bad guy in the current year of $0.65, but go away next year, right? And then, there's also the remaining hit on redetermination of expecting in 2024, which is also $0.65. So those two cancel each other out, you're looking at $4 and $2.

[Kevin Fischbeck, Bank of America]

Okay. So that $6 on the current guidance is not on the 20, 40 earnings power number.

[Mark Keim, CFO]

Correct.

[Kevin Fischbeck, Bank of America]

All right. And then I just want to go back one more time to the redeterminations because it's interesting because on the one hand, it sounds like you thought about redeterminations as a potential MLR pressure in your Medicaid MLR guidance, which is different, I think, than how you've talked about it in the past, but then throughout the call, you've kind of dismissed it as a potential pressure to MLR.

So just trying to understand a little bit finer like are you saying you've put it in, but you think it's set most 10 basis points or something like that, something kind of immaterial or how exactly are you thinking about and what exactly are you including in this year's guidance? And then I guess to build on that, if it is a pressure this year, would you expect that pressure to be higher or lower next year? Higher because more members are being determined or lower because states have more time to adjust rates? Thanks.

[Joe Zubretsky, President & CEO]

Kevin, I'll give it to Mark. We are not and haven't parsed all the specific trend factors that go into an MCR forecast for the Medicaid business, but we have been outperforming even the low end of our range, a range which produces best-in-class industry margins and we just think it's not prudent to continue to forecast that we'll continue to outperform the outperforming that range. So we call it a reversion to the mean.

We're forecasting an 88.5% for the Medicaid business, which is right in the middle of the range, citing medical cost pressures due to any of the items like flu, COVID, RSV and then, of course, any pressure that might be experienced with an acuity shift knowing that a significant acuity shift will probably be absorbed by retroactive rate increases. So I'm not going to parse it, but that's why we were somewhat conservative in forecasting the middle of our long-term Medicaid range rather than continuing to forecast that we outperform it.

[Mark Keim, CFO]

That's exactly right. So we finished last year at an 88% for the year. Our guidance anticipates an 88.5%, and we don't attribute any specific basis points to a driver. But in general, reversion to the mean flu, RSV, number of different things we could think about in there. Don't forget, we also have some new stores coming along, Iowa, the acquisition of My Choice Wisconsin. In general, just a little bit of conservatism, reversion to the mean, not attributing any basis points specifically to redetermination. But look, we've all had the conversation enough. We're acknowledging that, that's something that's potentially in there. in our reversion to the mean.

Now you also mentioned maybe what happens next year. So to the extent any of this starts to manifest it will largely be back-end loaded in the year, just given the way redetermination is going to play out. I think that gives all of us a lot of time to anticipate it but just as much work with our state partners to make sure that rates in the concept of actuarial soundness anticipate the same thing.

[Kevin Fischbeck, Bank of America]

All right. Thank you.

[Operator]

The next question comes from George Hill with Deutsche Bank. Please go ahead.

[George Hill]

Hi, guys. Is it working better this time around?

[Operator]

Yes. Thank you, sir.

[Joseph Zubretsky]

Yes, we hear you.

[George Hill]

Okay. Thank you, guys. Joe, and I think you kind of just touched on this in the last answer, but my question was around the $0.65 in implementation costs in 2023. I guess could you kind of break out the buckets that they're typically going to fall into. And again, this was just commented on, but I assume no part of that repeats in '24 that all goes away and there's no part of that cost structure that's durable.

[Joe Zubretsky, President & CEO]

I'll answer the last part of your question first. On the cost for -- obviously for Iowa, California and Nebraska, yes, those once spent should not repeat themselves. But as I said many times, and not tongue in cheek, I hope in the future, we continue to have one-time implementation costs on new contract wins can have a better spend than that. There are technology implementations, which are fixed in nature. And then, of course, you need to hire the people that are going to service these businesses in advance of the revenue stream, which is a major part of the $0.65 implementation cost. Mark?

[Mark Keim, CFO]

Right. I'll just build on that. So if you think about the $0.65, the way I think about it, about a third of it is IT, sort of a fixed component and about two-thirds of it is staffing, mostly highly variable, right? We have to staff up ahead of day one membership. So that's the way to think about it. It obviously, it comes to us ahead of when we start booking revenue. So I wouldn't say that it goes away specifically. What it does is it goes into the anticipated margin once we run these businesses. We've talked about $3.50 of same-store -- of new store embedded earnings here. That $3.50 is, of course, after operating costs. The reason we have $0.65 is we're not booking revenue yet. So $0.65, one-third, fixed; two-thirds variable, that's the right way to think about it.

[Joe Zubretsky, President & CEO]

Yeah. It goes away as a one-time item, but it becomes consumed into the run rate of the new contracts is the way to think about it.

[George Hill]

That’s helpful. Thank you.

[Operator]

Our last question comes from David Windley with Jefferies. Please go ahead.

[David Windley, Jefferies]

Good morning. Thanks for taking my question. I hope you can hear me. I have a few small ones. In your discussion around, the state's willingness to revisit these rates, as redetermination progresses. Do you have a sense of the urgency around that? Meaning, will they do that on a relatively short notice or will they want to have that discussion in the next rate cycle or after the majority of the redetermination in their state has played out.

[Joe Zubretsky, President & CEO]

We don't know that specifically. All we know is that they're aware of the theoretical possibility that there's an acuity shift in the book, likely, could result in prospective rate changes, but also retrospective rate changes. And it all has to be data driven. So to the point on timing, the data has to mature. The claims have to complete, the data has to be analyzed and then reasonable people will get in a room and figure out whether a rate change is necessary. So I would look at it, I don't know whether they're going to wait until the entire redetermination process is complete. But it's got to be data driven. So the data has to complete, and it has to be verifiable and actionable.

[Mark Keim, CFO]

And David, it's Mark. The fact that a number of these states have also led with this thought, unprompted to me is encouraging that will be somewhat proactive here.

[David Windley, Jefferies]

Okay. That's interesting. Second question is any thoughts on trends post-COVID in medical costs that are more durable and maybe distinction as to whether you're betting on that or not. So thinking about things like lower ER utilization and that type of things.

[Joe Zubretsky, President & CEO]

No, I think the medical trends we've experienced late in the year seem to have fallen into a nice pattern of, lack of volatility and understanding what COVID is actually costing sort of like on a run rate basis. It almost evolved into a $40 million to $50 million monthly run rate. And as long as it stays stable, as long as we know where the COVID infection rate is spiking, it certainly is -- the inpatient cost is certainly the more costly component, and that certainly hits the Medicare more than the Medicaid book. We have pretty good line of sight into what those services will cost us. But late in the year, it sort of settled into a nice pattern of $40 million to $50 million a month.

[David Windley, Jefferies]

And then lastly, Joe, I appreciate your comments on your -- it sounds like your M&A pipeline is still very robust. Does the cost of capital change in the environment impact cadence or appetite? Has it impacted expected valuation on the seller side?

[Joe Zubretsky, President & CEO]

No, not at all. We obviously measure the returns against our weighted average cost of capital. Obviously, we're earning more on the free cash now than we were before. So there's less of a drag. But no, it hasn't caused any change in momentum in terms of the appetite for counterparties in the market to want to speak to us and think about becoming part of the Molina enterprise.

[David Windley, Jefferies]

Great. That’s all I had. Thank you.

[Operator]

This concludes our question-and-answer session and Molina Healthcare's fourth quarter 2022 earnings call. Thank you for attending today's presentation. You may now disconnect.